Scientific Advisory Committee

Dr. Thomas Mendolia is a retired gastroenterologist in Elkin, North Carolina. He received his medical degree from New York College of Osteopathic Medicine. Dr. Mendolia has been in clinical practice for 17 years of which he spent most of his time in private practice at Tri-County Gastroenterology. He ran Northwest Piedmont Clinical Research where he oversaw 40 different clinical trials mainly focused on compounds related to various GI diseases. After retiring, he became the medical director for Surgical Centers across Florida and New Jersey. Dr. Mendolia is a founder of Medytox Solutions, Inc.

In addition to serving as Editor-In-Chief for CollabRx detailed interpretive reports, Dr. Lundberg is President and Chair of the Board of Directors of The Lundberg Institute, a Consulting Professor at Stanford University, and Editor at Large for Medscape from WebMD. Dr. Lundberg has more than 30 years combined experience as Editor in Chief of JAMA (The Journal of the American Medical Association), the 10 AMA specialty journals, AM News, Medscape, The Medscape Journal, e-Medicine from Web MD, and MedPage Today from Everyday Health. A frequent lecturer, radio and television guest, and a member of the Institute of Medicine of the National Academy of Sciences, the Industry Standard dubbed Dr. Lundberg “Online Healthcare’s Medicine Man” in 2000. Prior to CollabRx, Dr. Lundberg served as the President of the American Society for Clinical Pathology, Professor of Pathology and Associate Director of Laboratories at the Los Angeles County/USC Medical Center for 10 years, and for 5 years was the Professor and Chair of Pathology at the University of California, Davis. He served in the US Army during the Vietnam War, leaving as a lieutenant colonel after 11 years. Prior to his military service, Dr. Lundberg completed a clinical internship in Hawaii and a pathology residency in San Antonio. Called the medical Internet “pioneer” in 1995, Dr. Lundberg holds earned and honorary degrees from North Park College, Baylor University, the University of Alabama (Birmingham and Tuscaloosa), the State University of New York, Syracuse, Thomas Jefferson University and the Medical College of Ohio. Dr. Lundberg has worked in tropical medicine in Central America and Forensic Medicine in New York, Sweden, and England. His major professional interests are toxicology, violence, communication, physician behavior, patient safety, and health system reform.

Dr. Billings is a nationally recognized author, lecturer, consultant, professor and thought leader in genomic medicine and has served as the director of CollabRx, Inc. since 2014. A board certified internist and clinical geneticist, Dr. Billings’ career has been devoted to improving patient care by expanding the use of medically relevant genomic technologies in clinical settings, most recently as Chief Medical Officer of Life Technologies, Inc. He was Co-Founder and first Medical Director of the Cordblood Registry, Inc., past Senior Physician and SVP of Laboratory Corporation of America, Inc. (LabCorp), Co-Founder and Past Director of Omicia, Inc., Founder and EVP of GeneSage, Inc., and past Director of Ancestry.com, Inc.  Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. Dr. Billings holds a B.A. in history from UC San Diego, a M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University.

Dr. Christopher Mason is an Associate Professor of Computational Genomics and Neuroscience in the department of Physiology and Biophysics, the Feil Family Brain and Mind Research Institute, and the Institute for Computational Biomedicine at Weill Cornell Medical College (WCMC) in New York City, NY.  Dr. Mason develops and applies advanced techniques in genomics technology and integrative bioinformatics to discern the functional elements of the human genome and how they are disturbed in cancer and neuro-development, as well as how they respond to severe environmental pressures such as space travel. Dr. Mason holds two bachelor’s degrees (Genetics and Biochemistry) from the University of Wisconsin-Madison and performed his graduate thesis in Kevin White’s Laboratory at Yale University, building custom gene expression microarrays and developing bioinformatics tools. He then did two simultaneous post-doctoral fellowships at Yale: 1. Matthew State’s Laboratory on Neurogenetics at Yale Medical School, focusing on genetic mutations and genetic variations that lead to neuro-psychiatric disorders and brain malformations; and 2. a Fellow of Genomics, Ethics, and Law at Yale Law School’s Information Society Project (ISP), where Dr. Mason worked on gene patents, eventually leading to his work as an expert witness in the Supreme Court in Myriad v. AMP in 2013.

Dr. Kamran Ajami is currently the Medical Director at Westside Regional Hospital & Plantation General Hospital’s pathology department. Dr. Ajami attended Harvard Medical School and is a surgical pathologist with subspecialties in Gyn, Breast and Neuro- pathology. Dr. Ajami serves as the CEO of American Cytopathology Associates, PA, which supplies medical directors for laboratories.

Asad R. Zaidi, President & CEO is a biochemist and biomedical engineer graduated with honors from University of California, Irvine. He has been involved with the development of heart valves, artificial coronary arteries, membrane oxygenators, dialyzers and various in-vitro-diagnostic and biomedical devices since 1973. His experience of over 25 years spans the growth of biomedical devices in companies such as Shiley (Pfizer), C.R. Bard, Mitral Medical, Bicer Medical, and Medtronic. He has been responsible for licensing and transferring medical device manufacturing technology from Latin America to Canada and to England. His areas of expertise range from product development to patenting and production. He has written and assisted in FDA submissions of 510k pre-market notifications, investigational device exemptions (IDE), and pre-market authorizations (PMA).